<DOC>
	<DOCNO>NCT00947687</DOCNO>
	<brief_summary>The objective study demonstrate effectiveness , safety tolerability multiple daily dos inhale PUR003 , comparison placebo , healthy adult experimentally inoculate Influenza A/Wisconsin/67/2005 ( H3N2 ) virus .</brief_summary>
	<brief_title>Safety Efficacy Study Inhaled PUR003 Controlled Influenza Virus Challenge Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Male female subject age 18 45 year . In general good health determine screen evaluation ≤120 day prior doubleblind IMP administration day admittance quarantine . Seronegative ( NDA ) challenge virus . Have vaccinate influenza virus since 2006 ( determine medical history ) know influenza infection current season , define last 12 month . Presence evidence significant acute chronic , uncontrolled medical psychiatric illness . Abnormal pulmonary function evidence clinically significant abnormality spirometry . Health care worker ( include doctor , nurse , medical student ally healthcare professional ) anticipate patient contact within two week discharge quarantine . Intending travel ( country vaccination recommend high risk infection exist ) . Presence household member close contact ( 14 day discharge quarantine ) : le 3 year age ; know immunodeficiency ; receive immunosuppressant medication ; undergo soon undergo cancer chemotherapy within 28 day challenge . Subjects diagnose emphysema chronic obstructive pulmonary disease ( COPD ) ; elderly residing nursing home , affect severe lung disease medical condition ; transplant ( bone marrow solid organ ) organ recipient Subjects history asthma , COPD , pulmonary hypertension , reactive airway disease , chronic lung condition aetiology . Regular daily smoker 6 month prior study entry significant history tobacco use time ( ≥ total 10 pack year history = one pack day 10 year ) . Presence febrile illness symptom upper low tract respiratory infection 28 day prior viral inoculation ( subject may reevaluate enrolment resolution illness ) . Receipt investigational drug within 3 month , prior participation clinical trial influenza vaccine medication within 1 year participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>influenza</keyword>
	<keyword>healthy subject</keyword>
	<keyword>virus inoculation</keyword>
	<keyword>symptom score</keyword>
	<keyword>viral shed</keyword>
	<keyword>bioaerosol output</keyword>
</DOC>